ADRA2A and Sepsis: Compound 4n represents an important complementary pharmacological tool to studythe involvement of adrenoceptor subtypes in pathophysiologic conditionssuch as inflammation and sepsis and a novel candidate for furtherpreclinical development to treat ADRA2A-mediated pathologies.